Company / Cash & Equivalents
Twist Bioscience Corp Cash & Equivalents History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$183.0M
FY2025
5-year range
$183.0M / $465.8M
FY2021-FY2025
Trend
-19.1%
vs FY2024
Sector context
#97 of 209
Health Care
What the data says
At $183M, Twist Bioscience Corp's cash & equivalents ranks #97 of 209 in the Health Care sector. Cash & Equivalents has declined for 4 consecutive years, from $466M in FY2021 to $183M in FY2025.
Based on SEC 10-K filings.
$183M in FY2025 with a 5-year CAGR of +14.3%.
Declined from $286M to $183M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -21.5%
- 5-Year CAGR
- +14.3%
- 10-Year CAGR
- -
Sector benchmark
#97 of 209 in Health CareTop 46% of 209This company $183.0M Sector average $696.0M
▼
-73.7% below sector average
Key checks
Key Insights
- Twist Bioscience Corp's cash & equivalents has declined for 4 consecutive years.
- 5-year CAGR of +14.3%, indicating consistent growth.
- In FY2025, cash & equivalents decreased 19.1% year-over-year.
- Ranks #97 out of 209 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.79 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $183.0M | -19.1% |
| FY2024 | $226.3M | -21.0% |
| FY2023 | $286.5M | -24.4% |
| FY2022 | $378.7M | -18.7% |
| FY2021 | $465.8M | +397.3% |
| FY2020 | $93.7M | +100.4% |
| FY2019 | $46.7M | -42.1% |
| FY2018 | $80.8M | +158.6% |
| FY2017 | $31.2M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026